By Christopher Morrison
In the era of falling pharmaceutical productivity and major patent expiries, the question of what is a Big Pharma product...
As Big Pharma finds itself searching for products in smaller, more specialist markets, biotechs must decide whether it is better to take a product to market alone and reap the rewards while dealing with the risks, or take the money and run. Such is the happy dilemma for biotechs developing new drugs for HCV, an exploding market blessed with quick development timeframes and early proof-of-concept potential.
By Christopher Morrison
In the era of falling pharmaceutical productivity and major patent expiries, the question of what is a Big Pharma product...
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.